1. Home
  2. PRAX vs NTNX Comparison

PRAX vs NTNX Comparison

Compare PRAX & NTNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$331.79

Market Cap

9.6B

Sector

Health Care

ML Signal

HOLD

Logo Nutanix Inc.

NTNX

Nutanix Inc.

HOLD

Current Price

$36.33

Market Cap

10.9B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRAX
NTNX
Founded
2015
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
9.6B
10.9B
IPO Year
2020
2015

Fundamental Metrics

Financial Performance
Metric
PRAX
NTNX
Price
$331.79
$36.33
Analyst Decision
Strong Buy
Buy
Analyst Count
15
19
Target Price
$572.13
$62.29
AVG Volume (30 Days)
345.8K
3.3M
Earning Date
05-01-2026
05-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
227.45
EPS
N/A
0.57
Revenue
N/A
$2,537,927,000.00
Revenue This Year
N/A
$13.60
Revenue Next Year
$6,395.88
$13.18
P/E Ratio
N/A
$60.30
Revenue Growth
N/A
18.11
52 Week Low
$28.79
$34.01
52 Week High
$354.87
$83.36

Technical Indicators

Market Signals
Indicator
PRAX
NTNX
Relative Strength Index (RSI) 57.17 40.16
Support Level $282.49 $35.84
Resistance Level $327.65 $42.19
Average True Range (ATR) 17.60 1.97
MACD 2.86 -0.31
Stochastic Oscillator 81.68 29.14

Price Performance

Historical Comparison
PRAX
NTNX

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

About NTNX Nutanix Inc.

Nutanix Inc is engaged in cloud software, offering organizations a single platform for running applications and managing data anywhere. Its Nutanix Cloud Platform is designed to enable organizations to build a hybrid multicloud infrastructure, providing a consistent cloud operating model with a single platform for running applications and managing data in core data centers, at the edge, and in public clouds, all while supporting a variety of hypervisors and container platforms. The company operates a single operating and reportable segment based on a subscription business model. It conducts business in the United States, Europe, the Middle East and Africa, Asia Pacific, and other Americas, with key revenue generated from the United States.

Share on Social Networks: